PPA
CBIO

Parametric Portfolio Associates’s Crescent Biopharma CBIO Stock Holding History

Parametric Portfolio Associates’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-420
Closed -$127K – 3574
2021
Q1 		$127K Sell
420
-110
-21% -$39.4K ﹤0.01% 3945
2020
Q4 		$199K Sell
530
-161
-23% -$56.4K ﹤0.01% 3780
2020
Q3 		$212K Sell
691
-20
-3% -$7.64K ﹤0.01% 3637
2020
Q2 		$267K Buy
711
+601
+546% +$170K ﹤0.01% 3521
2020
Q1 		$25K Sell
110
-490
-82% -$187K ﹤0.01% 3883
2019
Q4 		$317K Buy
600
+440
+275% +$238K ﹤0.01% 3547
2019
Q3 		$69K Buy
+160
New +$103K ﹤0.01% 3875
2018
Q1 		– Sell
-684
Closed -$1.15M – 3941
2017
Q4 		$1.15M Sell
684
-87
-11% -$115K ﹤0.01% 2948
2017
Q3 		$1.08M Sell
771
-1
-0.1% -$1.17K ﹤0.01% 2998
2017
Q2 		$862K Buy
+772
New +$638K ﹤0.01% 3062

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's CBIO Position: Q2 2021 in Review

Parametric Portfolio Associates sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 420 shares — an estimated $127K sold.

Parametric Portfolio Associates first reported a position in CBIO in Q2 2017 and held it in 10 quarters. The position peaked at $1.15M in Q4 2017. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • Parametric Portfolio Associates reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 420 Crescent Biopharma shares in Q2 2021, an estimated $127K.
  • Parametric Portfolio Associates first reported a position in Crescent Biopharma in Q2 2017 and held it in 10 quarters.
  • Parametric Portfolio Associates's Crescent Biopharma position peaked at $1.15M in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Parametric Portfolio Associates's 13F filing for Q2 2021, filed 13 Aug 2021.